Today breast augmentation is performed all over the world. According to the American Society of Plastic Surgeons (ASPS) approximately 307,000 women in the United States (US) alone underwent breast augmentation surgery in 2008 and the demand for silicone implants is rising; the number of silicone breast implants increased from 35% in 2007 to 47% in 2008. It is estimated that Brazil is today the second major market for breast implants, with approximately 96,000 breast augmentation surgeries reported from September 2007 to August 2008, according to the Brazilian Society of Plastic Surgery (Sociedade Brasileira de Cirurgia Plástica \[SBCP\]). In Brazil, with the approval of the SBCP and the Brazilian Sanitary Surveillance Agency (Agência Nacional de Vigilância Sanitária \[ANVISA\]), silicone implants were used throughout the 14-year US Federal Drug Administration-issued silicone implant moratorium (1992--2006).

In 2002, the PERTHESE^®^ silicone implant line, manufactured by PEROUSE PLASTIE Laboratories in France, was adopted by Brazilian surgeons. The specific advantages of this silicone implant line include the close approximation in weight and consistency of the normal breast and the high-performance medical-grade silicone elastomer envelope that provides greater tear propagation resistance than the conventional silicone elastomer \[[@CR1]\]. These implants have a trilaminar silicone envelope that consists of an internal and an external layer of highly mechanically resistant medical-grade silicone elastomer and an intermediate barrier layer to significantly reduce gel bleed. The microtexturing gives the implant a relatively smooth feel, is identical from implant to implant, and is thought to help the implant remain soft while in contact with tissue \[[@CR1]\]. The microtextured PEROUSE PLASTIE products include the PERTHESE classic line of round implants with a low (TX), moderate (MX), or high profile (540), and the PERTHESE Esthea line of anatomical implants with a full (AX), high (EHP), or superhigh profile (ESHP) (Table [1](#Tab1){ref-type="table"}).Table 1Description of available study breast implantsShape of implant\
Profile/StyleVolume (cc)Classic (Round) High/540100, 125, 150, 175, 200, 230, 260, 280, 300, 325, 350, 400, 440, 500 Moderate/MX225 Low/TX185, 200, 220Esthea (Anatomical) Full/AX190, 210, 240, 260, 285, 300 Super High/ESHP295, 355 High/EHP225, 275

In 2005, Auclair and Staub \[[@CR2]\] published an article on the use of these implants in France but until now no data have been published on the use of PERTHESE implants in Brazil. We analyzed data collected from ten surgeons on a total of 1447 patients who underwent breast augmentation surgery in Brazil from 2002 through 2008. Surgeons were surveyed on the implant shape and volume used, surgical incision site, surgical plane of insertion, key postoperative complications, and surgeon and patient satisfaction.

Method {#Sec1}
======

A questionnaire was sent to 50 surgeons in Brazil who were using PERTHESE silicone breast implants. The questionnaire requested the following information on patients who underwent surgery: implant shape and volume, surgical incision site, surgical plane of insertion, key postoperative complications, and surgeon and patient satisfaction. Each surgery was performed according to a surgeon's free will and previous experience as well as the patient's wishes. The following data were collected:Implant shape and volume, determined by desire of the patient and advice of the surgeon based on the anatomical conditions of the patient (Table [2](#Tab2){ref-type="table"})Table 2Study implants, shape, and volumeShape of implant^a^Volume (cc)Cases (%)*N* = 1447Profile/StyleRound High/5401006 (0.4)1259 (0.6)15032 (2.2)17561 (4.2)200113 (7.8)230248 (17.1)260302 (20.9)280159 (11.0)300318 (22.0)32526 (1.8)35085 (5.9)40022 (1.5)4405 (0.3)5001 (0.1)  Subtotal1387 (95.9) Moderate/MX2252 (0.1)  Subtotal2 (0.1) Low/TX1852 (0.1)2001 (0.1)2204 (0.3)  Subtotal7 (0.5)Esthea Full/AX1903 (0.2)2101 (0.1)2405 (0.3)2603 (0.2)28514 (1.0)3003 (0.2)  Subtotal29 (2.0) Super High/ESHP2954 (0.3)3552 (0.1)  Subtotal6 (0.4)Total1447 (100) High/EHP2256 (0.4)27510 (0.7)  Subtotal16 (1.1)^a^With microtextured envelopeSurgical incision site (inframammary, periareolar, or transaxillary) (Table [3](#Tab3){ref-type="table"}), determined by the surgeon after discussion with the patient about potential scarringTable 3Surgical access and plane of insertionCases (%) (*N* = 1447)Surgical access Inframammary681 (47.1) Transaxillary486 (33.6) Periareolar280 (19.4)Surgical plane Subglandular802 (55.4) Submuscular645 (44.6)Surgical plane of insertion (submuscular plane or subglandular) according to surgeon's and patient's preference (Table [3](#Tab3){ref-type="table"})Patient's and surgeon's overall satisfaction with the surgery (excellent, good, regular, or unsatisfied) (Table [4](#Tab4){ref-type="table"})Table 4Surgeon and patient satisfaction (*N* = 1447)Excellent (%)Good (%)Regular (%)Unsatisfied (%)Surgeons84.014.60.90.6Patients79.617.72.10.6Ease of implantation compared to other breast implants (Table [5](#Tab5){ref-type="table"})Table 5Surgeon evaluation of ease of useEase of implantation compared to other breast implantsSurgeons (%) (*N* = 9)Easier6 (66.7)No difference3 (33.3)Number of cases with postoperative complications, including immediate complications such as seroma, hematoma, infection, and reoperations, and late complications such as capsular contracture, Baker grade I, II, III, and IV, and rupture (Table [6](#Tab6){ref-type="table"})Table 6Postoperative complicationsType of complicationCases (%) (*N* = 1447)Capsular contracture Baker III42 (2.9) Baker IV19 (1.3) Baker III/IV61 (4.2)Implant malposition/asymmetry^a^18 (1.2)Seroma, drainage needed6 (0.4)Hematoma, drainage needed4 (0.3)Reoperation Implant change3 (0.2) Due to asymmetry^a^1 (0.1)Rupture^b^0 (0.0)^a^One asymmetry case resulted in reoperation^b^Implant rupture was not evident for implants that were removed and was not suspected in the remaining population

Survey Results {#Sec2}
==============

Data were collected on 1447 breast augmentation patients who underwent surgery in Brazil between 2002 and 2008. The data were analyzed for implant shape and volume, surgical incision site, surgical plane of insertion, postoperative complications, and surgeon and patient satisfaction.

The majority (95.9%) of the implants used were round and high profile (Table [2](#Tab2){ref-type="table"}). Seventy-eight percent of the round, high-profile implants had a volume range of 200--300 cc. The remainder of the patients received round, moderate-profile (0.1%), round, low-profile (0.5%), anatomical, full-profile (2.0%), anatomical, superhigh-profile (0.4%), and anatomical, high-profile (1.1%) implants.

The results on surgical access show a preference for the traditional inframammary incision site (47.1%), followed by transaxillary (33.6%) and periareolar (19.4%; Table [3](#Tab3){ref-type="table"}). Subglandular and submuscular planes of insertion were used to a similar extent, with 55.4% subglandular and 44.6% submuscular (Table [3](#Tab3){ref-type="table"}).

Over 97% of surgeons and patients were satisfied with the surgery results, with 84.0% of surgeons and 79.6% of patients rating the surgery results as excellent. Less than 1% of the surgeons and patients were not satisfied with the surgery results (Table [4](#Tab4){ref-type="table"}).

When surveyed about ease of use, the majority of surgeons (66.6%) indicated that the PERTHESE implant was easier to implant that other breast implants (Table [5](#Tab5){ref-type="table"}).

The reported complications included capsular contracture (hard breast to palpation), implant malposition/asymmetry, hematoma, seroma, and reoperation. Capsular contracture, the most common complication found in this study, was reported in 61 (4.2%) patients: 42 (2.9%) patients experienced Baker grade III and 19 (1.3%) experienced Baker grade IV (Table [6](#Tab6){ref-type="table"}). Several patients also experienced seromas (6 patients, 0.4%) or hematomas (4 patients, 0.3%). Late postoperative asymmetry occurred in 18 (1.2%) patients. During the study period, 4 (0.3%) patients underwent reoperation and no cases of implant rupture were observed.

Discussion {#Sec3}
==========

After extensive laboratory research by the French company PEROUSE PLASTIE, the PERTHESE line of cohesive silicone gel breast implants was manufactured. Since the introduction of these breast implants in Brazil in 2002, there has been an increasing amount of available data on their use; however, these data have not been reported. This survey study on the use of PERTHESE implants in 1447 patients suggests that these implants are safe, easier to introduce than other implants, and result in a high level of surgeon and patient satisfaction.

Consistent with these findings, a review of the breast implant literature finds an overall high level of patient satisfaction with breast implant surgery and a relatively low level of postoperative complications (Table [7](#Tab7){ref-type="table"}). As in the current study, a general preference for the inframammary incision site has been reported; however, the frequency of submuscular implantation is often higher. It is important to note that these studies differ in their design and methods used for data analysis and, therefore, the data cannot be directly compared.

In addition, experience with today's thicker, more cohesive silicone gel implants demonstrates a low complication rate and high level of patient acceptance \[[@CR6], [@CR9]\]. The PERTHESE implants have a unique microtextured envelope that may contribute to the surgeon's favorable experience in this study and to the low level of complications experienced. It is also possible that these implants are less likely to rupture or result in gel bleed; however, studies over a longer period are necessary to address these questions.Table 7Review of the literature\[[@CR3]\]\[[@CR4]\]\[[@CR5]\]\[[@CR6]\]\[[@CR7]\]\[[@CR8]\]Current studyStudy methodSurveyMRI^d^ studyClinical trialComparative trialClinical trialClinical trialSurveyCountryCanadaSwedenUSSwedenUSUSBrazilPatients (*N*)118144492805524551,447Follow-up (years)Up to 25--934--666Up to 6DeviceStyle 410^a^Style 410^a^Style 410^a^Style 410^b^ and Vertex^d^MemoryGel^c^Natrelle^a^IPERTHESE^e^Volume (cc) RangeNot reported190--475Not reported240--500Not reportedNot reported100--500 Median280300270Implant location^f^ Subglandular32%31%16%72%Not reported30%55% Submuscular68%58%84%28%70%45% Unknown011%0000 Other0000\<1%0Incision site^f^ Inframammary81%74%87%86%Not reported46%47% Transaxillary03%\<1%\<2%13%34% Periareolar4%012%13%39%19% Unknown023%0000 Other15%01%02%0Overall patient satisfactionNot reported97%98%99%98%95%97%Capsular contracture, Baker III/IV0%6%2%23%10%15%4%Implant malposition/asymmetry1%Not reported3%Not reported08%1%Implant removal0\<1%5%Not reported8%13%\<1%^a^Manufactured by Allergan^b^Manufactured by Eurosilicone^c^Manufactured by Mentor^d^MRI = magnetic resonance imaging^e^Manufactured by PEROUSE PLASTIE^f^Implant location and incision site percentages are based on total number of devices implanted (Bengtson et al. \[[@CR5]\], 983 devices; Spear et al. \[[@CR8]\], 908 devices; Hedén et al. \[[@CR4]\], 286 devices) or total number of patients (Niechajev et al. \[[@CR6]\], 80 patients)
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